ClinicalTrials.gg
CompletedNCT02944734Updated Nov 22, 2016

Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

A Phase 2 interventional study of Candesartan Cilexetil 8mg and Candesartan Cilexetil 16mg in Essential Hypertension, sponsored by Shin Poong Pharmaceutical Co. Ltd.. Completed at 23 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2016-11-22.

Sponsored by Shin Poong Pharmaceutical Co. Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing amlodipine in Essential Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Amlodipine · Essential Hypertension.

Enrollment
11th of 34
392 · median 314
Started
2014
with 6 others
Phase 2
4 of 34
none open now
Registered
22nd of 34
by date

Among the 34 studies testing amlodipine in Essential Hypertension, this one is the 11th largest by enrollment, is one of 7 that started in 2014, is one of 4 in phase 2, and was the 22nd registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

1 of the 34 studies testing amlodipine in Essential Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing amlodipine in Essential Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to explore the optimal dose of fixed-dose combination of candesartan cilexetil and amlodipine besylate by examining the safety and efficacy of the combination therapy compared to each of the monotherapy in patients with essential hypertension.

03

Conditions studied

  • Essential Hypertension

Keywords

  • Candesartan
  • Amlodipine
  • Hypertension
  • Vascular Diseases
  • Cardiovascular Diseases
  • Antihypertensive Agents
  • Vasodilator Agents
  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin Receptor Antagonists
  • Calcium Channel Blockers
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients greater than or equal to 19 years of age
  2. Subject who was diagnosed with essential hypertension or after administer the antihypertensive drug (Subject who may temporarily suspend antihypertensive treatment based on doctor's decision)
  3. Subject who have voluntarily agreed to participate in the trial and signed the written form

Exclusion criteria

Exclusion Criteria:

  1. Subject with severe hypertension (in a selected arm with msSBP ≥ 200 mmHg or msDBP ≥ 115 mmHg) during the Screening and Randomized Trial.
  2. Subject with difference of the blood pressure of over 20 mmHg for SBP or 10 mmHg for diastolic blood pressure (DSP) between three consecutive measurements in a selected arm during the screening visit
  3. Secondary hypertension (such as, coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc.)
  4. Symptomatic orthostatic hypotension
  5. Severe heart failure( (NYHA) Class III/IV)
  6. Subject with acute coronary syndrome(myocardial infarction or unstable angina), peripheral vascular disease within the past 6 months
  7. History of switching to another Antiarrhythmic drugs(not including electrolyte correction), or received Cardioversion or ICU treatment within the past 6 months
  8. Type 1 diabetes mellitus or Uncontrolled Type 2 diabetes mellitus ( > 9.0%)
  9. Subject with Haemodynamic disturbance, heart valve disease with structural defects
  10. Severe cerebrovascular disease (stroke, cerebral infarction, or cerebral hemorrhage, etc. within the past 6 months)
  11. Severe eye disease (retinal hemorrhage, visual impairment, retinal microaneurysm, etc. within the past 6 months)
  12. diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.)
  13. Chronic inflammatory disease requiring continuous anti-inflammatory treatment
  14. Renal or liver impairment, or laboratory abnormalities such as Ccr: below 30ml/min or (AST) or Alanine Aminotransferase (ALT) > 3 x Upper Limit Normal ()
  15. Hypokalaemia(Serum potassium \< 3.5 mmol/L) or hyperkalaemia(Serum potassium > 5.5 mmol/L)
  16. Subject with gastrointestinal disease(such as Crohn's disease, gastric ulcer, acute or chronic pancreatitis) or history of gastrointestinal surgery(not including appendectomy or hernia surgery) that might significantly alter the absorption of the drug
  17. history of allergy or to Angiotensin II Receptor Blockers(Candesartan) or Calcium Channel Blocker(amlodipine)
  18. Subject with heredity defects such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption
  19. Subject requiring concomitant use of other antihypertensive or drugs( Tizanidine, dolasetron, Itraconazole, potassium, potassium-sparing diuretics, etc.) during the clinical trial
  20. history of malignant tumors within the past 5 years
  21. history of alcohol or drug abuse
  22. Pregnant women and lactating mothers
  23. Women who is planning to be pregnant during or 2 months after the study, or women or men who are not using medically acceptable methods of *

    * progestin oral or implant contraceptive, intra-uterine device, condom, partner with surgical sterilization, etc.

  24. Use of other products within the past 1 month
  25. Subject who are judged by the investigator unsuitable to participate in the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
392 participants (actual)

Study arms

  • Experimental
    Candesartan Cilexetil (CC) 8mg

    Candesartan Cilexetil 8mg, once a day for 8 weeks

    Drug: Candesartan Cilexetil 8mg

  • Experimental
    CC 16mg

    Candesartan Cilexetil 16mg, once a day for 8 weeks

    Drug: Candesartan Cilexetil 16mg

  • Experimental
    Amlodipine(AML) 5mg

    Amlodipine 5mg, once a day for 8 weeks

    Drug: Amlodipine 5mg

  • Experimental
    AML 10mg

    Amlodipine 10mg, once a day for 8 weeks

    Drug: Amlodipine 10mg

  • Experimental
    CC 8mg / AML 5mg

    Candesartan 8mg and Amlodipine 5mg, once a day for 8 weeks

    Drug: Candesartan Cilexetil 8mg · Drug: Amlodipine 5mg

  • Experimental
    CC 8mg / AML 10mg

    Candesartan 8mg and Amlodipine 10mg, once a day for 8 weeks

    Drug: Candesartan Cilexetil 8mg · Drug: Amlodipine 10mg

  • Experimental
    CC 16mg / AML 5mg

    Candesartan 16mg and Amlodipine 5mg, once a day for 8 weeks

    Drug: Candesartan Cilexetil 16mg · Drug: Amlodipine 5mg

  • Experimental
    CC 16mg / AML 10mg

    Candesartan 16mg and Amlodipine 10mg, once a day for 8 weeks

    Drug: Candesartan Cilexetil 16mg · Drug: Amlodipine 10mg

Interventions

  • Candesartan Cilexetil 8mg Daily oral administration for 8 weeks

    Also known as: Atacand 8mg

  • Candesartan Cilexetil 16mg Daily oral administration for 8 weeks

    Also known as: Atacand 16mg

  • Amlodipine 5mg Daily oral administration for 8 weeks

    Also known as: Norvasc 5mg

  • Amlodipine 10mg Daily oral administration for 8 weeks

    Also known as: Norvasc 10mg

06

What researchers measure

Primary outcomes

  1. Change mean sitting Diastolic Blood Pressure (msDBP) at week 8 compared to baseline

    Time frame: Week 8

Secondary outcomes

  1. Change mean sitting Diastolic Blood Pressure (msDBP) at week 4 compared to baseline

    Time frame: Week 4

  2. Change mean sitting Systolic Blood Pressure (msSBP) at week 4 and 8 compared to baseline

    Time frame: Week 4 and 8

  3. Proportion of patients achieving treatment goal at week 4 and 8: < 140/90 mmHg

    Joint National Committee VII Guideline Treatment goal: \< 140/90 mmHg (\< 130/80 mmHg, diabetic or chronic renal failure patient)

    Time frame: Week 4 and 8

  4. Blood Pressure Response rate at week 4 and 8: msSBP reduction ≥ 20 mmHg and msDBP reduction ≥ 10 mmHg

    Time frame: Week 4 and 8

07

Study locations

23 sites
  • Catholic University of Korea Bucheon St. Mary's Hospital
    Wonmi-gu, Bucheon, Korea, Republic of
  • Inje University Busan Paik Hospital
    Busanjin-gu, Busan, Korea, Republic of
  • Pusan National University Hospital
    Seo-gu, Busan, Korea, Republic of
  • Keimyung University Dongsan Medical Center
    Joong-gu, Daegu, Korea, Republic of
  • Kyungpook National University Hospital
    Joong-gu, Daegu, Korea, Republic of
  • Daegu Catholic University Medical Center
    Nam- gu, Daegu, Korea, Republic of
  • Dongguk University Ilsan Hospital
    Ilsandong-gu, Goyang-si, Gyeoggi-do, Korea, Republic of
  • Chonnam National University Hospital
    Dong-Gu, Gwangju, Korea, Republic of
  • Catholic University of Korea Uijeongbu St. Mary's hospital
    Uijeongbu-si, Gyeoggi-do, Korea, Republic of
  • Gachon University Gil Hospital
    Namdong-gu, Incheon, Korea, Republic of
  • St. Carollo General Hospital
    Suncheon-si, Jeollanam-do, Korea, Republic of
  • Wonju Severance Christian Hospital
    Wonju, Kangwon-Do, Korea, Republic of
  • Catholic University of Korea St. Paul's Hospital
    Dongdaemun-gu, Seoul, Korea, Republic of
  • KyungHee University Medical Center
    Dongdaemun-gu, Seoul, Korea, Republic of
  • Hallym University Kangdong Sacred Heart Hospital
    Gangdong-gu, Seoul, Korea, Republic of
  • Kyung Hee University Hospital at Gangdong
    Gangdong-Gu, Seoul, Korea, Republic of
  • VHS( Veterans Medical Service) Medical Center
    Gangdong-gu, Seoul, Korea, Republic of
  • Konkuk University Medical Center
    Gwangjin-gu, Seoul, Korea, Republic of
  • Seoul National University Hospital
    Jongro-gu, Seoul, Korea, Republic of
  • Catholic University of Korea Seoul St. Mary's Hospital
    Seocho-Gu, Seoul, Korea, Republic of
  • Korea University Anam Hospital
    Seongbuk-Gu, Seoul, Korea, Republic of
  • Catholic University of Korea Yeouido St. Mary's Hospital
    Yeongdeungpo-gu, Seoul, Korea, Republic of
  • Ulsan University Hospital
    Dong-gu, Ulsan, Korea, Republic of
08

References and documents

Publications

  • Sohn IS, Kim CJ, Ahn T, Youn HJ, Jeon HK, Ihm SH, Cho EJ, Chung WB, Chae SC, Kim WS, Nam CW, Park SM, Choi JY, Kim YK, Hong TJ, Lee HY, Cho JH, Shin ES, Yoon JH, Yang TH, Jeong MH, Lee JH, Park JI. Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial. Clin Ther. 2017 Aug;39(8):1628-1638. doi: 10.1016/j.clinthera.2017.06.014. Epub 2017 Jul 19. PubMed 28734660 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2016
First posted
Oct 26, 2016
Start
Sep 2014
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Last update
Nov 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02944734
Responsible party
Sponsor
First posted
Oct 26, 2016
Start date
Sep 2014
Primary completion
Dec 2015
Completion
Dec 2015
Last update
Nov 22, 2016

Study contacts

Chong-Jin Kim
study director · KyungHee University Hospital at Gangdong
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Candesartan cilexetil · Amlodipine

Start the discussion